Sysmex Europe Launches Automated Blood Testing Platform for Alzheimer’s Disease
The system uses routine blood draws to provide results in 17 minutes, offering an alternative to invasive diagnostic methods.
Category: Dementias & Alzheimer’s
Dementias & Alzheimer’s
Latest
Dementias & Alzheimer’s
Latest
NeuroVision Acquires Durin Life Sciences for Neurodegenerative Disease Diagnostics
NeuroVision Imaging has acquired Durin Life Sciences, combining blood-based biomarker tests with retinal imaging and telehealth to advance early detection of Alzheimer’s and Parkinson’s diseases.
Dementias & Alzheimer’s
Latest
C2N Diagnostics’ eMTBR-tau243 Plasma Assay Used in Alzheimer’s Phase 3 Trial Dataset
The biomarker showed independent associations with cognitive and functional decline, offering complementary information alongside p-tau217 in early symptomatic Alzheimer's disease.
Lucent Diagnostics Partners to Bring Blood-Based Alzheimer’s Testing to Community Settings
The collaboration will expand access to Alzheimer’s biomarker testing through mobile delivery to community centers, churches, and senior centers nationwide.
Read More
Quanterix Submits FDA 510(k) for Multi-Analyte Alzheimer’s Blood Test
The test uses five biomarkers and proprietary technology to detect amyloid brain plaques in patients with cognitive symptoms.
Read More
FDA-Cleared Blood Test for Alzheimer’s Assessment in Primary Care Now Available Nationwide
The Elecsys pTau-181 test helps primary care clinicians rule out Alzheimer’s disease in symptomatic patients aged 55 and older.
Read More
Circular Genomics Secures Exclusive Rights to Blood Test Technology for Alzheimer’s Disease
Circular Genomics has secured exclusive rights from Washington University and Max Delbrück Center to develop a blood-based Alzheimer’s test using circular RNA biomarkers.
Read More
Finger Prick Blood Test for Alzheimer’s Diagnosis Enters Large-Scale Trial
A large-scale international trial is evaluating a finger prick blood test for Alzheimer’s, analyzing three protein biomarkers as a potential alternative to PET scans and lumbar punctures.
Read More
Study Links Fat Transport Molecules to Alzheimer’s Risk Based on Genetics
Research finds lysophosphatidylcholines either promote or protect against disease depending on APOE ε4 gene status, with implications for personalized treatments.
Read More
ALZpath Blood Test Enables Large-Scale Alzheimer’s Disease Study
Study using pTau217 assay finds more than one in 10 adults over age 70 may be eligible for treatments to slow cognitive decline.
Read More
ALZpath, Siemens Healthineers Partner on Blood-Based Alzheimer’s Testing
Licensing agreement will integrate ALZpath’s pTau217 antibody into Siemens’ Atellica analyzer test menu for IVD Alzheimer’s diagnostics.
Read More
Blood Test Shows Obesity Speeds Alzheimer’s Development
A longitudinal study finds blood-based biomarkers more sensitive than PET scans in detecting obesity’s impact on Alzheimer’s pathology.
Read More
Plasma pTau Shows Promise as Early Endpoint in Alzheimer’s Trials
New cross-trial analysis supports the biomarker’s potential to predict clinical benefit, reinforcing biomarker-driven trial designs.
Read More
Circular Genomics Raises $15M to Advance Circular RNA Platform for Alzheimer’s Detection
The financing will accelerate clinical validation and commercial readiness of brain-derived blood biomarkers based on circular RNA technology.
Read More
Neurogen Biomarking Partners with Tasso for Needle-Free Blood Collection in Alzheimer’s Testing
The collaboration aims to make home-based Alzheimer’s biomarker testing more accessible through virtually painless blood collection technology.
Read More
Digital Cognitive Test Helps Identify Primary Care Patients Who Need Alzheimer’s Blood Biomarker Testing
Researchers say the digital assessment improves early identification of patients likely to benefit from blood biomarker testing for Alzheimer’s disease.
Read More
Lab Validates FDA-Cleared Blood-Based Alzheimer’s Biomarker Assay Under EU Regulations
The validation enables its use as a blood-based biomarker for inclusion and exclusion in clinical trials in both the United States and Europe.
Read More
New FDA-Cleared Blood Test Moves Alzheimer’s Assessment into Primary Care
Roche’s Elecsys pTau181 assay gives clinical labs a key role in the initial evaluation of cognitive decline, helping to rule out amyloid pathology earlier in the diagnostic process.
Read More